Shahsavari Gholamreza, Raoufi Amir, Toolabi Aram, Hosseninejadmir Nahid, Ahmadvand Hassan, Safariebrahimsarabie Mehdi
Assistant Professor, Department of Clinical Biochemistry, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
Assistant Professor, Department of Cardiology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
ARYA Atheroscler. 2017 Nov;13(6):282-287.
The major aim of this study was evaluating the effect of atorvastatin treatment on thiobarbituric acid reactive substances (TBARS), ferric reducing the ability of plasma (FRAP), small dense low-density lipoprotein cholesterol (sdLDL) and lipid profile in coronary artery disease (CAD) patients.
This study was carried out on 83 patients with angiographically proven coronary artery stenosis (52 men and 31 women) at Shahid Madani Hospital, Khorramabad, Iran, in 2015. The patients were divided into the 3 groups. 27 patients were classified statins consumption less than 6 days, 28 patients for 6 to 90 days, and 28 patients for more than 90 days. The level of sdLDL, lipid profile, TBARS and FRAP were assayed.
FRAP levels of patients that received atorvastatin for more than 90 days (832 ± 101) were significantly elevated (P = 0.01) compared to the patients received atorvastatin less than 6 days (688 ± 75), whereas the levels of TBARS diminished significantly (P = 0.04). Also, the levels of total cholesterol (TC) and LDL-C were significantly decreased after 3 months of atorvastatin receiving (158 as compared to patients that consumed atorvastatin less than 6 days), (P = 0.02 and 0.03, respectively). The level of sdLDL was slightly increased with long-time consumption of atorvastatin (37 ± 14) in patients in comparison with patients that received atorvastatin less than 6 days (32 ± 15) (P = 0.06), but was not significant.
The serum level of TBARS decreased and the serum level of FRAP increased in patients with long-time receiving atorvastatin. Therefore, atorvastatin contributes to the lowering oxidative stress in these patients.
本研究的主要目的是评估阿托伐他汀治疗对冠状动脉疾病（CAD）患者硫代巴比妥酸反应性物质（TBARS）、血浆铁还原能力（FRAP）、小而密低密度脂蛋白胆固醇（sdLDL）和血脂谱的影响。
2015年，在伊朗霍拉马巴德的沙希德·马达尼医院对83例经血管造影证实有冠状动脉狭窄的患者（52例男性和31例女性）进行了本研究。患者分为3组。27例患者他汀类药物服用时间少于6天，28例患者服用6至90天，28例患者服用超过90天。测定sdLDL、血脂谱、TBARS和FRAP水平。
服用阿托伐他汀超过90天的患者的FRAP水平（832±101）与服用阿托伐他汀少于6天的患者（688±75）相比显著升高（P = 0.01），而TBARS水平显著降低（P = 0.04）。此外，服用阿托伐他汀3个月后，总胆固醇（TC）和低密度脂蛋白胆固醇（LDL-C）水平显著降低（与服用阿托伐他汀少于6天的患者相比分别为158），（P分别为0.02和0.03）。与服用阿托伐他汀少于6天的患者（32±15）相比，长期服用阿托伐他汀的患者的sdLDL水平略有升高（37±14）（P = 0.06），但不显著。
长期服用阿托伐他汀的患者血清TBARS水平降低，血清FRAP水平升高。因此，阿托伐他汀有助于降低这些患者的氧化应激。
